clinical trial · NCT07479485
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
Lepu Biopharma Co., Ltd.·phase2·not yet recruiting·n = 160
Hepatocellular CarcinomaMRG006AMRG006AMRG006A
brief summary
This is an open-label, multicenter, Phase I/II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of MRG006A in combination with immune checkpoint inhibitors and targeted therapy in patients with advanced hepatocellular carcinoma (HCC).
started
Apr 1, 2026
primary completion
Apr 1, 2028
completion
Apr 1, 2029
last updated
Mar 18, 2026
official title
An Open-Label, Multicenter, Phase I/II Study Evaluating MRG006A in Combination With Immune Checkpoint Inhibitors and Targeted Therapy in Patients With Advanced Hepatocellular Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol